E G Levine|D Raghavan - JoVE Visualize

Showing results (91-100 of 160) with videos related to

Pageof 16

Sort By:

European Journal of Cancer (Oxford, England : 1990)|January 20, 1999

The clinical development of paclitaxel and the paclitaxel/carboplatin combinationG N Schwartz, L Pendyala, H Kindler, et al.

European Journal of Cancer (Oxford, England : 1990)|January 1, 1993

A randomised cross-over trial of antiemetic therapy for platinum-based chemotherapy. Improved control with an intensive multiagent regimenM Findlay, R J Simes, K Cox, et al.

Annals of Internal Medicine|January 1, 1988

Cytogenetic abnormalities predict clinical outcome in non-Hodgkin lymphomaE G Levine, D C Arthur, G Frizzera, et al.

Blood|December 1, 1985

There are differences in cytogenetic abnormalities among histologic subtypes of the non-Hodgkin's lymphomasE G Levine, D C Arthur, G Frizzera, et al.

European Journal of Cancer & Clinical Oncology|May 1, 1987

Patient treatment preference in advanced breast cancer: a randomized cross-over study of doxorubicin and mitozantroneR Stuart-Harris, R J Simes, A S Coates, et al.

British Medical Journal (Clinical Research Ed.)|October 25, 1986

Randomised comparison of procedures for obtaining informed consent in clinical trials of treatment for cancerR J Simes, M H Tattersall, A S Coates, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1990

Phase II trial of carboplatin in the management of malignant mesotheliomaD Raghavan, P Gianoutsos, J Bishop, et al.

Seminars in Oncology|October 1, 1995

Phase I study of paclitaxel and carboplatin: implications for trials in head and neck cancerP Creaven, D Raghavan, L Pendyala, et al.

The Annals of Thoracic Surgery|April 1, 1982

Mediastinal nonseminomatous germ cell tumors: the role of combined modality therapyN J Vogelzang, D Raghavan, R W Anderson, et al.

The Medical Journal of Australia|May 18, 1992

Combination chemotherapy with cisplatin, vindesine and mitomycin-C for advanced, inoperable non-small-cell lung cancerM Stockler, D Raghavan, B C McCaughan, et al.

Pageof 16

Showing results (91-100 of 160) with videos related to

Sort By:

Pageof 16

European Journal of Cancer (Oxford, England : 1990)|January 20, 1999

The clinical development of paclitaxel and the paclitaxel/carboplatin combinationG N Schwartz, L Pendyala, H Kindler, et al.

European Journal of Cancer (Oxford, England : 1990)|January 1, 1993

A randomised cross-over trial of antiemetic therapy for platinum-based chemotherapy. Improved control with an intensive multiagent regimenM Findlay, R J Simes, K Cox, et al.

Annals of Internal Medicine|January 1, 1988

Cytogenetic abnormalities predict clinical outcome in non-Hodgkin lymphomaE G Levine, D C Arthur, G Frizzera, et al.

Blood|December 1, 1985

There are differences in cytogenetic abnormalities among histologic subtypes of the non-Hodgkin's lymphomasE G Levine, D C Arthur, G Frizzera, et al.

European Journal of Cancer & Clinical Oncology|May 1, 1987

Patient treatment preference in advanced breast cancer: a randomized cross-over study of doxorubicin and mitozantroneR Stuart-Harris, R J Simes, A S Coates, et al.

British Medical Journal (Clinical Research Ed.)|October 25, 1986

Randomised comparison of procedures for obtaining informed consent in clinical trials of treatment for cancerR J Simes, M H Tattersall, A S Coates, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1990

Phase II trial of carboplatin in the management of malignant mesotheliomaD Raghavan, P Gianoutsos, J Bishop, et al.

Seminars in Oncology|October 1, 1995

Phase I study of paclitaxel and carboplatin: implications for trials in head and neck cancerP Creaven, D Raghavan, L Pendyala, et al.

The Annals of Thoracic Surgery|April 1, 1982

Mediastinal nonseminomatous germ cell tumors: the role of combined modality therapyN J Vogelzang, D Raghavan, R W Anderson, et al.

The Medical Journal of Australia|May 18, 1992

Combination chemotherapy with cisplatin, vindesine and mitomycin-C for advanced, inoperable non-small-cell lung cancerM Stockler, D Raghavan, B C McCaughan, et al.

Pageof 16